Pharming Group (PHARM.AS) Osake Kurssi
Pharming Group Kurssi
Viimeisten 19 vuoden aikana Pharming Groupn liikevaihto kasvoi 48,9 % vuodessa ja ylsi 326,12 M USD:een. Osakekohtainen tulos on laskenut 29,3 % vuodessa viimeisten 7 vuoden aikana. Pharming Groupn nettomarginaali 0,8 % on laskenut verrattuna 8,4 %:iin muutama vuosi sitten. Pharming Groupn 12 kuukauden konsensustavoitehinta on 2,29 USD, noin yli kurssia 132,7 %. 14 analyytikosta 13 suosittaa ostoa — kokonaiskonsensus on Osta.
Pharming Group osakekurssi
Pharming Group liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Pharming Group -osakkeesta
Pharming Group NV operates under a unique business model. The company specializes in the development and commercialization of innovative biotherapeutics using its proprietary technology platform, known as the recombinant human C1 esterase inhibitor (rhC1INH). This technology allows Pharming Group to produce and deliver recombinant human proteins, addressing unmet medical needs in diseases such as hereditary angioedema (HAE) and lysosomal storage disorders. By leveraging their scientific expertise and strategic partnerships, Pharming Group NV aims to improve the quality of life for patients and create value for their stakeholders.
Pharming Group NV is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Pharming Group NV in the market include Biocryst Pharmaceuticals, CSL Behring, Grifols, and Takeda Pharmaceutical Company Limited.
Pharming Group NV is a biopharmaceutical company with a rich history and remarkable background. The company was established in 1988, headquartered in the Netherlands. Pharming focuses on the development and commercialization of innovative protein replacement therapies and precision medicines utilizing its proprietary technology platform. The company is renowned for its pioneering work in the field of recombinant human plasma proteins, particularly Recombinant Human C1 Inhibitor (rhC1INH). Pharming Group NV has successfully developed and marketed these life-saving treatments for hereditary angioedema (HAE) and acquired angioedema (AAE), significantly improving the lives of patients worldwide. With an impressive track record of scientific expertise and substantial market presence, Pharming Group NV continues to be a leading player in the biopharmaceutical industry.
Pharming Group NV has achieved several significant milestones. Notably, the company received approval for its lead product, Ruconest, by regulatory authorities in the United States and Europe. This approval allows Pharming Group NV to market Ruconest for the treatment of acute hereditary angioedema attacks, enhancing the company's market presence. Additionally, Pharming Group NV has successfully expanded Ruconest's sales and commercial footprint, securing distribution agreements in various countries. The company's consistent efforts in research and development have resulted in the exploration of new therapeutic areas, such as Pompe disease. Pharming Group NV's commitment to innovation and attaining regulatory approvals has paved the way for its growth and success in the biopharmaceutical industry.
Pharming Group NV is primarily present in several countries and regions worldwide. The company has a strong presence in the United States, where it operates its North American headquarters. Additionally, Pharming Group NV has a significant presence in Europe, with offices and distribution networks in various countries such as the Netherlands, Germany, France, Italy, and the United Kingdom. Furthermore, the company has expanded its reach into Asia, particularly in important markets like Japan and South Korea. With its global presence, Pharming Group NV is able to effectively deliver its innovative biopharmaceutical products and therapies to patients across different continents.
Pharming Group NV represents values of innovation, collaboration, and patient-centricity. As a leading biotech company, Pharming is committed to developing innovative therapies for patients with unmet medical needs. They prioritize collaboration by partnering with research institutions, healthcare professionals, and patient organizations to advance scientific knowledge. Pharming's corporate philosophy revolves around improving the quality of life for patients through the development and commercialization of novel therapies. Their dedication to scientific excellence, integrity, and global outreach enables them to provide effective and life-changing therapies for patients around the world.
Analyytikot asettavat tällä hetkellä Pharming Group-osakkeelle keskimääräisen tavoitehinnan 2,46 USD (mediaani: 2,29 USD), mikä merkitsee +150,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 14 analyytikkoarvioon.
14 analyytikkoa arvioi tällä hetkellä Pharming Group-osaketta: 13 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Pharming Group-yhtiöltä 381,11 M USD liikevaihtoa ja 0,02 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Pharming Group-osake noteerataan hintaan 0,88 EUR (0,98 USD).
Pharming Group-osake (PHARM.AS) on listattuna 9 pörssissä, muun muassa: London (0QCO.L), SIX (Zürich) (PHGN.SW), Frankfurt (PHGN.F), München (PHGN.MU), Düsseldorf (PHGN.DU), Amsterdam (PHARM.AS).
The Pharming Group NV is a biopharmaceutical company specialized in the development of innovative therapies for rare genetic diseases. The company is based in Leiden, Netherlands and is listed on the Euronext Amsterdam exchange. Pharming's business model is based on the research and development of biopharmaceuticals for the treatment of rare genetic diseases. The company focuses particularly on rare immune system disorders, including Hereditary Angioedema (HAE) and Lymphocytic Varicosis (LV). Pharming also conducts clinical trials for the treatment of other rare diseases. Pharming's products include Ruconest, a recombinant C1 esterase inhibitor (rhC1INH) used for the treatment of HAE. Ruconest is Pharming's flagship product and is marketed globally. The company has also developed a biosimilar version of Ruconest, which is produced under the brand name RucON. Pharming also has a pipeline of future products in development, including a recombinant factor VIII for the treatment of Hemophilia A and a recombinant factor IX for the treatment of Hemophilia B. The company is also working on the development of therapies for the treatment of rarer diseases such as Vascular Ehlers-Danlos Syndrome (EDS). Pharming pursues a diversified business model with a focus on research and development, production, and marketing of biopharmaceuticals. The company also operates its own manufacturing facility to ensure the production of biopharmaceuticals. Pharming also follows a strategic acquisition strategy to expand its product pipeline and increase market presence. Pharming's business model is based on a strong research and development pipeline, efficient production, a differentiated product range, and a strong marketing strategy to increase its presence in the markets. Pharming's focus on rare genetic diseases and continuous innovation in the treatment of these diseases make the company an important player in the biopharmaceutical market.
odotettu liikevaihto Pharming Group on 381,11 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Pharming Group on 15,83 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Pharming Group:n hinta-voitto-suhde (P/E) on tällä hetkellä 47,08. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Pharming Group-osakkeen arvostusta.
Pharming Group:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,96. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Pharming Group-osakkeen arvostuskennuslukuna.
Pharming Group:n Eulpool-laatuscore on 5/10.
Pharming Group:n ISIN on NL0010391025. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Pharming Group:n WKN on A1H65A. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Pharming Group:n ticker on PHARM.AS. Tämä pörssinoteeraus käytetään Pharming Group-osakkeiden kauppaan pörssissä.
Pharming Group osake
Pharming Group vertaisryhmä
Pharming Group Ticker
Pharming Group FIGI
Kaikki tunnusluvut ja syvällinen analyysi Pharming Group:sta
Meidän osakeanalyysimme Pharming Group-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Pharming Group:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: